Home » Newsletters » BioWorld Science

BioWorld Science

March 15, 1999

View Archived Issues

New treatment strategy successful in patients with severe CHF

Cancer therapeutics joint venture IBC Pharmaceuticals receives start-up funding

Toprol-XL effective in heart failure; MERIT-HF trial results presented

Long-term treatment with phen-fen associated with valvular abnormalities

Eptifibatide lowers MI incidence, heart muscle injury in ACS patients

Telomeres and telomerase linked to cancer, age-related changes

Pliva and Althexis collaborate on structure-based design of new antibiotics

New DAG analogues acting as PKC agonists or antagonists

Zeria patents new series for BPH

New patent issues covering Cytoclonal's novel methods of producing paclitaxel

Orally active analgesic agents in development at Otsuka

N-type calcium channel inhibitors described by Ono

GABA-A receptor ligands from MS&D for Alzheimer's disease

Volunteer study suggests that CMI-977 may be superior to zileuton in both efficacy and safety

New market introduction for Seretide

Kanebo's Na+/H+ exchange inhibitor is a promising treatment for acute coronary syndrome

Venous responsiveness to NE is enhanced in the presence of aspirin

BTG licenses anti-CD3 antibody to LeukoSite

Health Canada approves Rebetron for chronic HCV

FDA grants priority review status, sets date for advisory committee review of Actos

Spanish market introduction announced for antirejection MAb

SkyePharma completes DepoTech acquisition

Hollis-Eden to initiate HIV/AIDS trials with HE-2000 in South Africa

Improvement in seasonal allergic rhinitis following preventive treatment with rhuMAb-E25

Effexor XR receives FDA approval for treatment of GAD

CysLT1 antagonists show potential as Rx for chronic urticaria

Hemosol to begin multinational phase III trials of Hemolink

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...